Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FR3Z
|
|||
| Drug Name |
Aminoarylpyridine derivative 1
|
|||
| Synonyms |
PMID26161698-Compound-42
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cyclin-dependent kinase 9 (CDK9) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.